{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', '9.1.2.', 'Ethical Review', 'The protocol, protocol amendments, ICF, Investigator Brochure, and other relevant documents', '(eg, advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and', 'approved by the IRB/IEC before the study is initiated.', 'Any amendments to the protocol will require IRB/IEC approval before implementation of', 'changes made to the study design, except for changes necessary to eliminate an immediate', 'hazard to study patients.', 'The Investigator will be responsible for the following:', 'Providing written summaries of the status of the study to the IRB/IEC annually or more', 'frequently in accordance with the requirements, policies, and procedures established by', 'the IRB/IEC', 'Notifying the IRB/IEC of SAEs or other significant safety findings as required by', 'IRB/IEC procedures', 'Providing oversight of the conduct of the study at the site and adherence to requirements', 'of 21 CFR, ICH guidelines, the IRB/IEC, European Regulation 536/2014 for clinical', 'studies (if applicable), and all other applicable local regulations', '9.1.3.', 'Study Documentation, Confidentiality, and Records Retention', 'Patients will be assigned a unique identifier by the Sponsor. Any patient records or datasets that', 'are transferred to the Sponsor will contain the identifier only; patient names or any information', 'which would make the patient identifiable will not be transferred.', 'The patient must be informed that his/her personal study-related data will be used by the Sponsor', 'in accordance with local data protection law. The level of disclosure must also be explained to', 'the patient.', 'The patient must be informed that his/her medical records may be examined by Clinical Quality', 'Assurance auditors or other authorized personnel appointed by the Sponsor, by appropriate', 'IRB/IEC members, and by inspectors from regulatory authorities.', '9.1.4.', 'End of the Study', 'The end of the study is defined as last patient last visit.', '9.1.5.', 'Discontinuation of the Clinical Study', 'The Sponsor or designee reserves the right to close the study site or terminate the study at any', 'time for any reason at the sole discretion of the Sponsor. Study sites will be closed upon study', 'completion. A study site is considered closed when all required documents and study supplies', 'have been collected and a study site closure visit has been performed.', 'The Investigator may initiate study site closure at any time, provided there is reasonable cause', 'and sufficient notice is given in advance of the intended termination.', 'Reasons for the early closure of a study site by the Sponsor or Investigator may include but are', 'not limited to:', 'Property of the Sanofi Group - strictly confidential', '71']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-003', '(Sanofi Genzyme EFC14768)', '27 Jun 2018', 'Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC', \"or local health authorities, the Sponsor's procedures, or GCP guidelines\", 'Inadequate recruitment of patients by the Investigator', 'Discontinuation of further study intervention development', '9.2.', 'Data Quality Control and Quality Assurance', '9.2.1.', 'Data Handling', 'Source documents provide evidence for the existence of the patient and substantiate the integrity', \"of the data collected. Source documents are filed at the Investigator's site.\", 'Data reported or entered in the eCRF that are transcribed from source documents must be', 'consistent with the source documents or the discrepancies must be explained. The Investigator', 'may need to request previous medical records or transfer records, depending on the study. Also,', 'current medical records must be available.', 'All patient data relating to the study will be recorded on printed or eCRF unless transmitted to', 'the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible for', 'verifying that data entries are accurate and correct by physically or electronically signing the', 'eCRF.', 'The Investigator must maintain accurate documentation (source data) that supports the', 'information entered in the eCRF.', 'The Investigator must permit study-related monitoring, audits, IRB/IEC review, and regulatory', 'agency inspections and provide direct access to source data documents.', 'The Sponsor or designee is responsible for the data management of this study including quality', 'checking of the data.', '9.2.2.', 'Study Monitoring', 'Study monitors will perform ongoing source data verification to confirm that data entered into', 'the eCRF by authorized site personnel are accurate, complete, and verifiable from source', 'documents; that the safety and rights of patients are being protected; and that the study is being', 'conducted in accordance with the currently approved protocol and any other study agreements,', 'ICH GCP, and all applicable regulatory requirements.', 'Records and documents, including signed ICFs, pertaining to the conduct of this study must be', 'retained by the Investigator for 15 years after study completion unless local regulations or', 'institutional policies require a longer retention period. No records may be destroyed during the', 'retention period without the written approval of the Sponsor. No records may be transferred to', 'another location or party without written notification to the Sponsor.', '9.2.3.', 'Audits and Inspections', 'Periodically, the Sponsor or its authorized representatives audit clinical investigative sites as an', 'independent review of core trial processes and documents to determine whether these activities', 'were conducted, and data were recorded, analyzed, and accurately reported according to the', 'Property of the Sanofi Group - strictly confidential', '72']\n\n###\n\n", "completion": "END"}